Drug Makers Sought Higher Pay For Inpatient 'Transformative Therapies' At OMB Meeting

By Michelle M. Stein / April 18, 2018 at 7:26 PM
Brand drug maker representatives met with CMS and White House budget officials to push for higher Medicare hospital inpatient reimbursement through changes to the MS-DRG system and the New Technology Add-on Payments, about which industry has raised concerns for years. The Feb. 23 meeting was attended by industry representatives from the Biotechnology Innovation Organization -- which requested the meeting -- Gilead Sciences, Kite Pharma, Johnson & Johnson and Celgene. They discussed next year's proposed hospital inpatient pay rule, according to...


Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.